TY - JOUR
T1 - Adult precision medicine
T2 - Learning from the past to enhance the future
AU - Ghiaseddin, Ashley
AU - Minh, Lan B.Hoang
AU - Janiszewska, Michalina
AU - Shin, David
AU - Wick, Wolfgang
AU - Mitchell, Duane A.
AU - Wen, Patrick Y.
AU - Grossman, Stuart A.
N1 - Funding Information:
Conflict of interest statement . The authors do not have conflicts of interest related to the information in this manuscript. Details of paid consulting and funding not related to this content are below. A.G. has received personal fees from Monteris Medical and Novocure. A.G. has also received research funding support from Orbus Therapeutics. L.H.M. declares that she has no conflict of interest. M.J. declares that she has no conflict of interest. D.S. declares that he has no conflict of interest. W.W. is a paid consultant for Bayer, Merck Sharp and Dohme, and Roche (with the compensation received by the University of Heidelberg), and reports receiving other commercial research support from Roche, Apogenix, and Pfizer. D.A.M. has intellectual property licensed or optioned to Celldex Therapeutics, Annias Immunotherapeutics, and iOncologi. D.A.M. has served as an advisor/consultant to Bristol-Myers Squibb, Tocagen, and Oncorus, and is cofounder of iOncologi, Inc., an immuno-oncology biotechnology company. Neither any reagent nor any funding from these organizations was used in this study. P.Y.W. is a member of the Speaker’s Bureau for Merck and Prime Oncology. P.Y.W. serves as a consultant/advisory board member for Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines. P.Y.W. also has received research support from Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines. S.A.G. declares that he has no conflict of interest.
Funding Information:
This research has been funded by Adam Michael Rosen Foundation, ReMission Alliance Against Brain Tumors, and Wells Brain Tumor Research Fund at UF Foundation.
Publisher Copyright:
© 2020 The Author(s) 2020.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Despite therapeutic advances for other malignancies, gliomas remain challenging solid tumors to treat. Complete surgical resection is nearly impossible due to gliomas' diffuse infiltrative nature, and treatment is hampered by restricted access to the tumors due to limited transport across the blood-brain barrier. Recent advances in genomic studies and next-generation sequencing techniques have led to a better understanding of gliomas and identification of potential aberrant signaling pathways. Targeting the specific genomic abnormalities via novel molecular therapies has opened a new avenue in the management of gliomas, with encouraging results in preclinical studies and early clinical trials. However, molecular characterization of gliomas revealed significant heterogeneity, which poses a challenge for targeted therapeutic approaches. In this context, leading neuro-oncology researchers and clinicians, industry innovators, and patient advocates convened at the inaugural annual Remission Summit held in Orlando, FL in February 2019 to discuss the latest advances in immunotherapy and precision medicine approaches for the treatment of adult and pediatric brain tumors and outline the unanswered questions, challenges, and opportunities that lay ahead for advancing the duration and quality of life for patients with brain tumors. Here, we provide historical context for precision medicine in other cancers, present emerging approaches for gliomas, discuss their limitations, and outline the steps necessary for future success. We focus on the advances in small molecule targeted therapy, as the use of immunotherapy as an emerging precision medicine modality for glioma treatment has recently been reviewed by our colleagues.
AB - Despite therapeutic advances for other malignancies, gliomas remain challenging solid tumors to treat. Complete surgical resection is nearly impossible due to gliomas' diffuse infiltrative nature, and treatment is hampered by restricted access to the tumors due to limited transport across the blood-brain barrier. Recent advances in genomic studies and next-generation sequencing techniques have led to a better understanding of gliomas and identification of potential aberrant signaling pathways. Targeting the specific genomic abnormalities via novel molecular therapies has opened a new avenue in the management of gliomas, with encouraging results in preclinical studies and early clinical trials. However, molecular characterization of gliomas revealed significant heterogeneity, which poses a challenge for targeted therapeutic approaches. In this context, leading neuro-oncology researchers and clinicians, industry innovators, and patient advocates convened at the inaugural annual Remission Summit held in Orlando, FL in February 2019 to discuss the latest advances in immunotherapy and precision medicine approaches for the treatment of adult and pediatric brain tumors and outline the unanswered questions, challenges, and opportunities that lay ahead for advancing the duration and quality of life for patients with brain tumors. Here, we provide historical context for precision medicine in other cancers, present emerging approaches for gliomas, discuss their limitations, and outline the steps necessary for future success. We focus on the advances in small molecule targeted therapy, as the use of immunotherapy as an emerging precision medicine modality for glioma treatment has recently been reviewed by our colleagues.
KW - blood-brain barrier (BBB)
KW - glioma
KW - next-generation sequencing (NGS)
KW - precision medicine
KW - tumor heterogeneity
UR - http://www.scopus.com/inward/record.url?scp=85126636260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126636260&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdaa145
DO - 10.1093/noajnl/vdaa145
M3 - Article
C2 - 33543142
AN - SCOPUS:85126636260
SN - 2632-2498
VL - 3
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdaa145
ER -